Table 5 Expression of Smurf2 relative to ER, PR and HER2 status in non-malignant and malignant breast tumors
| Â | Non-Malignant | Malignant | P-value | |
|---|---|---|---|---|
(n = 22) | (n = 62) |  | ||
Smurf2 | ER | Â | Â | Â |
no/mild | no/mild | 14(63.64%) | 6(9.68%) | < 0.001 |
no/mild | mod/intense | 2(9.09%) | 0(0.00%) | Â |
mod/intense | no/mild | 2(9.09%) | 38(61.29%) | Â |
mod/intense | mod/intense | 4(18.18%) | 18(29.03%) | Â |
Smurf2 | PR | Â | Â | Â |
no/mild | no/mild | 9(40.91%) | 4(6.45%) | < 0.001 |
no/mild | mod/intense | 7(31.82%) | 2(3.23%) | Â |
mod/intense | no/mild | 1(4.55%) | 41(66.13%) | Â |
mod/intense | mod/intense | 5(22.73%) | 15(24.19%) | Â |
Smurf2 | HER2 | Â | Â | Â |
no/mild | no/mild | 12(54.55%) | 2(3.23%) | < 0.001 |
no/mild | mod/intense | 4(18.18%) | 4(6.45%) | Â |
mod/intense | no/mild | 4(18.18%) | 25(40.32%) | Â |
mod/intense | mod/intense | 2(9.09%) | 31(50.00%) | Â |